BioClinica to Highlight New Trident IWR Release at DIA
BioClinica, Inc.announced a new release of Trident IWR, the latest addition to its best-in-class suite of eClinical applications. BioClinica will highlight Trident and other new product offerings at booth #1417, providing demonstrations of BioClinica’s Integrated Clinical Trial Solutions, including:
- Trident IWR Randomization to Express EDC
- Express CRF Status to OnPoint CTMS and Clinical Payment Manager
- Trident + Optimizer 360 Degree Clinical Supplies Forecasting and Management
- Unified Reporting
- Customer Portals
- Microsoft Office Interoperability
- Ad Hoc Reporting
BioClinica will also participate in a clinical solutions showcase for the Microsoft platform, where they will demonstrate BioClinica’s open, standards-based architecture within the Microsoft Connected Life Sciences Framework guidance.
To see the benefits of this solution, please visit Microsoft at booth #1111 and BioClinica at booth #1417.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
